OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 04:46 UTC. Every row links to its source record.

TBX3 T-box transcription factor 3

ENSG00000135111 · protein coding · Open Targets profile

Transcriptional repressor involved in developmental processes (PubMed:10468588). Binds to the palindromic T site 5'- TTCACACCTAGGTGTGAA-3' DNA sequence, or a half-site, which are present in the regulatory region of several genes (PubMed:12000749). Probably plays a role in limb pattern formation (PubMed:10468588). Required for mammary placode induction, and maintenance of the mammary buds during development (By similarity). Involved in branching morphogenesis in both developing lungs and adult mammary glands, via negative modulation of target genes; acting redundantly with TBX2 (By similarity). Required, together with TBX2, to maintain cell proliferation in the embryonic lung mesenchyme; perhaps acting downstream of SHH, BMP and TGFbeta signaling (By similarity). Involved in modulating early inner ear development, acting independently of, and also redundantly with, TBX2 in different subregions of the developing ear (By similarity). Acts as a negative regulator of PML function in cellular senescence (PubMed:22002537). {ECO:0000250|UniProtKB:P70324, ECO:0000269|PubMed:10468588, ECO:0000269|PubMed:12000749, ECO:0000269|PubMed:22002537}.

In 12 of 15 cancers, the evidence for TBX3 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.77breast adenocarcinomabreast adenocarcinomabreast adenocarcinoma: somatic 0.81colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.57polyp of colonpolyp of colonpolyp of colon: germline 0.68luminal A breast carcinomaluminal A breast carcinomaluminal A breast carcinoma: germline 0.66skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61breast lobular carcinomabreast lobular carcinomabreast lobular carcinoma: somatic 0.61superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61breast carcinoma by gene expression pro…breast carcinoma by gene expression profilebreast carcinoma by gene expression profile: somatic 0.61mixed lobular and ductal breast carcino…mixed lobular and ductal breast carcinomamixed lobular and ductal breast carcinoma: somatic 0.61skin squamous cell carcinomaskin squamous cell carcinomaskin squamous cell carcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61esophageal melanomaesophageal melanomaesophageal melanoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Med-Quality Pocket
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.23021000623703003 (upper bound 0.3810400068759918). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of TBX3's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of TBX3's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.